Table 4
Open in new tab

Main clinical characteristics of matched groups

VariableGroup 1 (n = 65)Group 2 (n = 65)P-value
Age (years)67 ± 667 ± 91
Men (%)50501
Holter data
 PVCs (Nr/24 h)1120 ± 19691246 ± 18160.70
 Processed PVCs (Nr/24 h)150 ± 156178 ± 2180.43
 Mean heart rate (b.p.m.)70 ± 969 ± 90.40
 NSVT (%)1160.004
CVRFs
 Diabetes (%)001
 Hypertension (%)69770.42
 Dyslipidemia (%)58720.13
 Smoking (%)19191
 Drug therapy
 β-Blockers (%)4276<0.001
 ACE-inhibitors (%)35480.15
 Statins (%)2877<0.001
 Diuretics (%)41500.37
LVEF (%)61 ± 650 ± 14<0.001
HRT parameters
 TO (%)−1.24 ± 2.2–0.53 ± 1.20.03
 TS (ms/RR)5.08 (2.95–7.30)2.18 (1.19–4.64)<0.001
VariableGroup 1 (n = 65)Group 2 (n = 65)P-value
Age (years)67 ± 667 ± 91
Men (%)50501
Holter data
 PVCs (Nr/24 h)1120 ± 19691246 ± 18160.70
 Processed PVCs (Nr/24 h)150 ± 156178 ± 2180.43
 Mean heart rate (b.p.m.)70 ± 969 ± 90.40
 NSVT (%)1160.004
CVRFs
 Diabetes (%)001
 Hypertension (%)69770.42
 Dyslipidemia (%)58720.13
 Smoking (%)19191
 Drug therapy
 β-Blockers (%)4276<0.001
 ACE-inhibitors (%)35480.15
 Statins (%)2877<0.001
 Diuretics (%)41500.37
LVEF (%)61 ± 650 ± 14<0.001
HRT parameters
 TO (%)−1.24 ± 2.2–0.53 ± 1.20.03
 TS (ms/RR)5.08 (2.95–7.30)2.18 (1.19–4.64)<0.001

PVCs, premature ventricular complexes; NSVT, non-sustained ventricular tachycardia; CVRFs, cardiovascular risk factors; ACE, angiotensin converting enzyme; LVEF, left ventricular ejection fraction; HRT, heart rate turbulence; TO, turbulence onset; TS, turbulence slope.

Table 4
Open in new tab

Main clinical characteristics of matched groups

VariableGroup 1 (n = 65)Group 2 (n = 65)P-value
Age (years)67 ± 667 ± 91
Men (%)50501
Holter data
 PVCs (Nr/24 h)1120 ± 19691246 ± 18160.70
 Processed PVCs (Nr/24 h)150 ± 156178 ± 2180.43
 Mean heart rate (b.p.m.)70 ± 969 ± 90.40
 NSVT (%)1160.004
CVRFs
 Diabetes (%)001
 Hypertension (%)69770.42
 Dyslipidemia (%)58720.13
 Smoking (%)19191
 Drug therapy
 β-Blockers (%)4276<0.001
 ACE-inhibitors (%)35480.15
 Statins (%)2877<0.001
 Diuretics (%)41500.37
LVEF (%)61 ± 650 ± 14<0.001
HRT parameters
 TO (%)−1.24 ± 2.2–0.53 ± 1.20.03
 TS (ms/RR)5.08 (2.95–7.30)2.18 (1.19–4.64)<0.001
VariableGroup 1 (n = 65)Group 2 (n = 65)P-value
Age (years)67 ± 667 ± 91
Men (%)50501
Holter data
 PVCs (Nr/24 h)1120 ± 19691246 ± 18160.70
 Processed PVCs (Nr/24 h)150 ± 156178 ± 2180.43
 Mean heart rate (b.p.m.)70 ± 969 ± 90.40
 NSVT (%)1160.004
CVRFs
 Diabetes (%)001
 Hypertension (%)69770.42
 Dyslipidemia (%)58720.13
 Smoking (%)19191
 Drug therapy
 β-Blockers (%)4276<0.001
 ACE-inhibitors (%)35480.15
 Statins (%)2877<0.001
 Diuretics (%)41500.37
LVEF (%)61 ± 650 ± 14<0.001
HRT parameters
 TO (%)−1.24 ± 2.2–0.53 ± 1.20.03
 TS (ms/RR)5.08 (2.95–7.30)2.18 (1.19–4.64)<0.001

PVCs, premature ventricular complexes; NSVT, non-sustained ventricular tachycardia; CVRFs, cardiovascular risk factors; ACE, angiotensin converting enzyme; LVEF, left ventricular ejection fraction; HRT, heart rate turbulence; TO, turbulence onset; TS, turbulence slope.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close